Immunopharmacotherapy (Q20326): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: budget (P474): 579,749.118 euro) |
(Changed an Item: Fixing rounding issue) |
||||||||||||||
| Property / budget | |||||||||||||||
579,749.12 Euro
| |||||||||||||||
| Property / budget: 579,749.12 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / budget: 579,749.12 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / budget: 579,749.12 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 23:27, 24 September 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Immunopharmacotherapy |
Project in Czech Republic financed by DG Regio |
Statements
12,319,668.75 Czech koruna
0 references
14,493,727.95 Czech koruna
0 references
85.0 percent
0 references
1 May 2017
0 references
30 September 2022
0 references
Univerzita Palackého v Olomouci
0 references
49°35'41.89"N, 17°16'31.12"E
0 references
77900
0 references
Realizací projektu budou vytvořeny odborné výukové materiály a zajištěno adekvátní personální zázemí pro akreditaci mezioborového DSP Imunofarmakoterapie efektivně spojujícího lékařskou imunologii a biologii s biotechnologií a technologií biokompatibilních nanopartikulárních dopravních systémů umožňující přípravu preventivních i terapeutických imunopreparátů. Absolventi budou schopni úspěšně řešit úkoly základního výzkumu, průmyslového výzkumu a experimentálního vývoje v imunofarmakoterapii. (Czech)
0 references
Through the implementation of the project, training materials will be created and adequate staffing resources are provided for the accreditation of the IORP-interbranch SAA, effectively combining medical immunology, and biocompatible biotechnology and biocompatible nano-sensitive transport systems enabling the preparation of both preventive and therapeutic immunoslides. Graduates will be able to successfully address the tasks of fundamental research, industrial research and experimental development in immunopharmacotherapy. (English)
0 references
Identifiers
CZ.02.2.69/0.0/0.0/16_018/0002665
0 references